Viking Therapeutics financials
$31.81−3.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M | -$42.7M | -$32.7M | -$26.2M | -$19.1M | -$13.8M |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M | -$39.5M | -$25.8M | -$22.1M | -$20.6M | -$14.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | $-0.54 | $-0.36 | $-0.38 | $-0.79 | $-0.90 |
| EBITDA | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M | -$38.6M | -$31.8M | -$25.4M | -$18.0M | -$13.7M |
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M | -$21.8M | -$24.8M | -$18.8M | -$14.8M | -$11.1M |
| Free cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$215.6M | — | — | — | — | — |
| Diluted shares | 112.7M | 109.0M | 94.3M | 76.8M | 77.2M | 72.6M | 72.0M | 57.6M | 26.0M | 16.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $165.8M | $26.7M | $55.5M | $36.6M | $26.4M | $29.1M |
| Short-term investments | $539.9M | $875.9M | $306.6M | $118.9M | $175.7M | $219.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M | $256.5M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M | $12.2M |
| Shareholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M | $244.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology